Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells $871,660.70 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 13,187 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the transaction, the chief executive officer owned 3,792,739 shares in the company, valued at $250,700,047.90. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 29th, Christopher Richard Anzalone sold 51,726 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $69.13, for a total value of $3,575,818.38.
• On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.44, for a total value of $861,385.84.
• On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $67.66, for a total transaction of $909,688.70.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $65.69 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market cap of $8.93 billion, a P/E ratio of -821.02 and a beta of 1.21. The firm’s 50 day moving average price is $56.34 and its 200-day moving average price is $35.95. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $29,000. Salomon & Ludwin LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $34,000. Federated Hermes Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $52,000. Smartleaf Asset Management LLC increased its holdings in Arrowhead Pharmaceuticals by 2,186.5% in the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,618 shares during the last quarter. Finally, Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $34,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Multiple firms raised price targets (Goldman Sachs to $85, Morgan Stanley to $81, Chardan to $80), signaling renewed analyst optimism about Arrowhead’s prospects and giving the share price directional upside. Article Title
• Positive Sentiment: Arrowhead released interim Phase 1/2a obesity data showing meaningful fat reductions and a combination result that nearly doubled four‑month weight loss with tirzepatide — news that triggered investor interest and bullish media coverage. Article Title
• Positive Sentiment: Unusually heavy call‑option activity and earlier intraday spikes indicate speculative/bullish positioning around the obesity data. Article Title
• Neutral Sentiment: Some analysts and commentators flagged small sample sizes and incomplete datasets in the obesity update, meaning clinical significance and reproducibility remain uncertain until larger cohorts and full data are published. Article Title
• Negative Sentiment: Arrowhead filed to sell $500M of convertible senior notes due 2032 and $200M of common stock — a material capital raise that raises dilution and financing‑cost concerns for equity holders. Article Title
• Negative Sentiment: Large insider sales by senior executives (multiple recent Form 4 filings showing significant share disposals) are adding to market concern about near‑term selling pressure. Article Title

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group boosted their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday. Morgan Stanley boosted their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Bank of America lifted their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Royal Bank Of Canada increased their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $71.89.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.